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ABSTRACT 
 
To assess the role of sortilin in the sorting and trafficking of sphingolipid activator proteins (SAPs) the function of 
sortilin was abolished by a dominant-negative mutant and by the use of RNAi. Mutant sortilin lacking the carboxyl-
terminal region that contains the sorting signal abolished the trafficking of SAPs to the lysosomes. Both sortilin and 
SAPs were retained in the Golgi apparatus. The use of chemically synthesized siRNA effectively blocked the 
trafficking of SAPs to the lysosomes as well. Additionally, we created a stable COS-7 cell line transfected with the 
pSilencer 3.1 H1 neo vector containing a selected siRNA template oligonucleotide (small hairpin interference RNA) 
where the levels of sortilin were greatly suppressed. The elimination of sortilin by this method will permit to 
determine whether or not sortilin is involved in a general mechanism of lysosomal sorting that involves the trafficking 
of various soluble lysosomal proteins other than SAPs. 
 
 
INTRODUCTION 
 
Protein trafficking in eukaryotic cells involves a series of 
protein-protein interactions between the cargo and the 
proteins that form the transport carrier. Cargo proteins 
are selected for sorting to specific destinations by coat 
proteins or by receptors that in turn interact with coat 
proteins (1). Various organelles have a repertoire of 
receptors and coat proteins that specify the final 
destination of the cargo protein. The coat proteins cause 
trafficking vesicles to bud from donor membranes and to 
traffic to acceptor membranes. Major sites of vesicle 
formation and budding include the endoplasmic 
reticulum, the plasma membrane and the Golgi 
apparatus. The Golgi apparatus is the site of sorting for 
newly synthesized proteins destined to the lysosomal 
compartment. Two different types of proteins are sorted 
 
 
to the lysosomes, transmembrane and soluble lysosomal 
proteins. Due to their specific characteristics these two 
types of proteins use different sorting mechanisms.  
 
Lysosomal membrane proteins such as LAMPs and 
LIMPs interact directly with the coat-proteins, AP-1 and 
AP-3. These 2 complexes are members of the multimeric 
adaptor complexes that also include AP-2 and AP-4. 
Each of these complexes is composed of a large subunit 
(β1-4), a medium subunit (µ1-4), a small subunit (σ1-4) 
and a non-homologous subunit (γ,  α,  δ,  ε) (2). Coat 
proteins interact with lysosomal membrane proteins at 
two different sites. Tyrosine based motifs (YXXΦ, where 
X is any amino acid and Φ is a bulky hydrophobic amino 
acid) from proteins such as LAMP-1 and CD63 bind to 
AP-1 and AP-3 via their µ1 and µ3 subunits respectively 
while dileucine motifs (DXXLL) from proteins such as     
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tyrosinase and LIMP-II bind to γ-σ1 and δ-σ3 hemi-
complexes (3). Disruption of these interactions causes 
missorting of the cargo to the plasma membrane.  
 
The Golgi apparatus has a second set of coat proteins 
known as Golgi-localized, γear-containing ARF-binding 
proteins (GGAs). The GGAs are three homologous 
monomeric adaptor proteins (4). While the multimeric 
adaptors are directly recruited to the Golgi membrane by 
the transmembrane proteins LAMPs, LIMPS and 
tyrosinase, the monomeric adaptors bind to 
transmembrane receptors such as the mannose 6-
phosphate receptor (M6P-R) (4) and sortilin (5). 
Interestingly, both receptors bind soluble lysosomal 
proteins such as cathepsins and various other soluble 
hydrolases in the case of the M6P-R and sphingolipid 
activator proteins (prosaposin and GM2AP) in the case of 
sortilin (6). Several reports have demonstrated that 
disruption of GGAs interferes with the sorting of soluble 
cargos to the lysosomal compartment (4, 7). 
 
Sphingolipid Activator Proteins (SAPs) are a group of 
five lysosomal proteins involved in the catabolism of 
lipids in the lysosome (8, 9). Four of the proteins, the 
saposins, originate from the lysosomal cleavage of the 
common precursor protein prosaposin (10). The fifth SAP 
is the GM2 activator protein (11). The five SAPs are 
effectors of the enzymes that breakdown 
glycosphingolipids. We have recently reported that 
prosaposin and GM2 activator protein require sortilin to 
traffic to the lysosomal compartment by using dominant 
negative competitors and RNAi technology to suppress 
sortilin and GGAs (6). In the present paper, we discuss 
the use of these dominant negative proteins and RNAi, 
their potential benefits and disadvantages in the study of 
protein trafficking to the lysosomes. 
 
MATERIALS AND METHODS 
 
Rationale 
 
Previous reports demonstrated that sortilin could bind 
GGAs via its cytoplasmic tail. This suggested a possible 
role for sortilin in the transport of proteins to the 
lysosomal compartment. Paradoxically, no cargo had 
been demonstrated to bind or use this potential sorting 
receptor. Since SAPs had been shown to reach the 
lysosomes in an M6P-R independent manner, we 
hypothesized that sortilin was the sorting receptor for 
SAPs. To test this hypothesis, we developed and used a 
dominant negative form of sortilin, which lacked the 
GGA binding motif. Additionally, we developed a set of 
siRNA probes to knockdown sortilin expression in COS-
7 cells and we examined the effect of sortilin inactivation 
on the transport of SAPs. In this paper we are extending 
our RNAi results by including a plasmid-based 
expression approach that produces hairpin RNA species 
capable of preventing the synthesis of sortilin. This new 
approach appears to be more effective since the 
expression plasmid produces short hairpin RNA 
molecules constitutively and allows for selection of RNAi 
positive clones. 
 
Dominant negative procedure 
 
A useful tool to investigate the function of a targeting 
protein is to introduce into the cell a mutant version to 
compete with the endogenous version of the protein and 
cause a malfunction in the system. To test whether or not 
sortilin was the sorting receptor for SAPs, we 
constructed a mutant protein of sortilin that lacked its 
sorting signal in the cytoplasmic tail without affecting its 
capacity to bind SAPs in the luminal compartment of the 
Golgi apparatus. We expected this mutant protein to be 
retained in the Golgi apparatus or to be missorted to the 
plasma membrane. Additionally, we expected to observe 
distinct biochemical and immunostaining patterns for 
SAPs due to the inability of the sorting receptor to traffic 
to the lysosomes. 
 
The mutant protein was designed using primers to 
eliminate the carboxy-terminal tail of sortilin, which 
contains the lysosomal sorting signal. Since this assay is 
based on the competition of truncated versus 
endogenous sortilin the success of this experiment 
depended upon the higher level of expression of the 
recombinant protein. Another requirement for this 
experiment was the introduction of an epitope (myc-tag) 
that allows distinguishing the recombinant from 
endogenous sortilin. To meet these requirements the 
truncated protein was cloned into the pcDNA3.1 vector, 
a mammalian expression vector. Since this vector is 
designed to add a c-terminal myc-tag to the cloned 
protein, we were able to distinguish mutant sortilin in 
COS-7 cells and in western blot analysis with an anti-
myc antibody (Invitrogen, Burlington, ON). To examine     
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the localization of mutant sortilin, we transiently 
transfected COS-7 cells with the pcDNA3.1 vector using 
a DEAE/Dextran chloroquine phosphate technique. Cells 
were then incubated for 48 hours to allow the mutant 
protein to be expressed. The dominant negative form of 
sortilin lacking its sorting tail was detected by 
immunofluorescence confocal microscopy and western 
blot analysis. 
 
RNAi procedures 
 
siRNA: Designing a small interfering RNA (siRNA) is an 
important step for successful knockdown of a target 
protein. One potential obstacle is the fact that the design 
is almost random, in that no specific sequence is 
guaranteed to knockdown the targeted mRNA. Several 
companies, including Ambion (Austin, TX) and 
Dharmacon (Lafayette, CO), provide algorithms to assist 
in the design of siRNAs. The key requirement of this 
approach is to select several sequences of a protein that 
are not found in any other proteins searched in Blast. 
This allows the design of specific siRNAs that will only 
target the desired protein. Although this is a clear 
advantage of siRNA, a recent report suggests that the 
specificity achieved by this procedure may not be as high 
as initially thought (12). As well, the starting 
requirements for selecting an siRNA sequence include a 
sequence beginning with an AA di-nucleotide, having no 
stretches of greater than four T’s, and a G/C content 
between 30-50% (13). After selecting the specific 
sequences from the target protein, the siRNAs may be 
synthesized using commercial kits or via a commercial 
laboratory. Although this procedure is much less 
expensive than producing a mouse KO, sometimes the 
generation of siRNAs can prove to be costly. Since 
commercial siRNAs can range from 200-500 U.S. dollars 
per sample the use of this service could be a good 
alternative if the selected sequence is already known to 
work. siRNAs can be ordered from Qiagen (Mississauga, 
ON) and Dharmacon (Lafayette, CO) or other 
laboratories. In our case we produced our own siRNAs 
in situ using a kit from Ambion (Austin, TX). Thus, for 
the same price is it is possible to generate up to 12 
different siRNAs. 
 
O n c e  t h e  s i R N A  i s  p r o d u c e d  i t  m u s t  b e  t r a n s i e n t l y  
transfected into a mammalian cell line. Several methods 
are available for transfecting culture cells with either 
plasmids that transcribe RNAi or siRNA directly. Roche 
(Laval, QC) and Invitrogen (Burlington, ON) have 
available liposome-based systems. In fact, Invitrogen 
developed a transfection reagent specific for oligo 
siRNAs called Oligofectamine. These products work well 
and are used extensively although cost can be a factor in 
some cases. In our hands, a simple DEAE-
dextran/Chloroquine phosphate technique worked 
optimally. According to this procedure COS-7 cells are 
plated overnight in serum free media and transfected 
with the recommended amount of siRNA. The cells are 
placed at 37°C for 48 hours. In our experience, incubation 
times may vary greatly. In some cases, two doses of 
siRNA transfection are required, with an interval of 48 or 
72 hours. We normally incubate our cells for a total of six 
days. 
 
Hairpin RNAi: The hairpin consists of a single-stranded 
RNA containing two regions of complementary 
sequences that refold into a double-stranded loop region 
and a connecting loop stem with a 3’ terminal uridine 
tract. Based on our siRNA results we selected an internal 
sortilin sequence (AAGGTGGTGTTAACAGCAGAG) for 
designing the short hairpin RNA (shRNA). The sequence 
was subcloned into the plasmid-based expression vector 
pSilencer 3.1 H1-neo that contains a strong H1 RNA pol 
III promoter (Ambion, Austin, TX). We used 
Lipofectamine 2000 (Invitrogen, Burlington, ON) as 
described by the manufacturer to transfect the plasmid 
and selected for resistant cells to neomycin (GIBCO, 
Burlington, ON), which expressed constitutively the 
shRNA. The purpose of this strategy is to initiate the 
production of shRNA to trigger dicer cleavage and led to 
the sortilin mRNA silencing. 
 
RESULTS AND DISCUSSION 
 
Effect of dominant negative sortilin 
 
The objective of this experiment was to introduce a 
dominant negative mutant sortilin in COS-7 cells to 
compete with endogenous sortilin and cause the 
retention and/or missorting of their putative ligands, i.e., 
sphingolipid activator proteins (SAPs). This technique 
has been used extensively to abolish the function of 
signaling proteins (14). In this case  we constructed a 
mutant sortilin that lacked the cytoplasmic sorting 
signal, thereby retaining the receptor in the Golgi or 
missorting it to the plasma membrane. We hypothesized 
that if sortilin was the receptor for SAPs, the lysosomal 
localization of these proteins should also change with the 
localization of the mutant protein. Using an anti-myc 
antibody, our results indicated a steady state production     
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and retention of mutant sortilin in the Golgi apparatus, 
as shown by its co-localization staining with the anti-
Golgin antibody (Figs. 1.1-1.3). Since the mutant protein 
was retained in the Golgi apparatus, we predicted that 
the cargo of this receptor should remain in the same 
compartment and/or be missorted to the extracellular 
space.  To examine the effect of the dominant-negative 
construct on the lysosomal trafficking of SAPs, COS-7 
cells were immunostained with either anti-prosaposin 
(Figs. 1.2-1.3) or anti-GM2AP antibodies (6) after transient 
transfection with the mutant sortilin. Control COS-7 cells 
stained for SAPs showed punctate structures that co-
localized with LysoTracker or other lysosomal markers 
such as cathepsin B and LAMP-2 (6). Cells expressing 
mutant sortilin exhibited little or no punctate staining. 
This was interpreted as a demonstration of reduced 
amounts of the SAPs in the lysosomal compartment as 
compared to the non-transfected cells. On the other 
hand, mutant sortilin had no effect on the lysosomal 
localization of cathepsin B, a protein that requires the 
M6P-R to traffic to lysosomes (6). 
 
Effect of sortilin siRNAs 
 
Using the Ambion kit we synthesized six siRNAs against 
sortilin. To determine the effect of the siRNAs we 
examined both mRNA and protein levels using RT-PCR 
and Western blotting and/or immunofluorescence. First, 
we isolated mRNA from transfected and non-transfected 
(control) cells using a Qiagen’s Rneasy kit (Mississauga, 
ON), and performed RT-PCR. Our results showed that 
siRNA 1 (AGGTGGTGTTAACAGCAGAG) and siRNA 3 
(AATGTTCCAATGCCCCACTC) successfully inhibited 
the expression of sortilin mRNA in COS-7 cells. To verify 
that transfection did not inhibit the expression of 
unrelated proteins we examined the level of β-actin 
mRNA. β-Actin is expressed constitutively in most cells. 
The levels of β-actin transcripts were measured by RT-
PCR in normalized samples of transfected or non-
transfected cells. Our results showed that β-actin 
transcripts were not affected by the siRNA treatment (6). 
Cell lysates were simultaneously prepared from COS-7 
cells transfected or not with sortilin siRNAs and run on 
a n  S D S - P A G E  g e l .  I m m u n o blotting confirmed that 
siRNAs 1 and 3 were most effective in reducing the 
amount of sortilin, but not β-actin in transfected cells. To 
verify the immunoblotting results, we evaluated the level 
of sortilin in these cells using immunofluorescence and 
confocal microscopy. Confocal microscopy demonstrated 
that sortilin siRNA abolished the immunostaining of the 
anti-sortilin antibody (Figs. 1.4-1.6). 
After confirming the inhibitory effect of the sortilin 
siRNA we tested the hypothesis that sortilin is the 
sorting receptor for SAPs. To this effect we used siRNA 
(sequence 1) which knockdown sortilin most efficiently 
in COS-7. We predicted that knocking down sortilin 
would affect the localization of SAPs. To assess this 
prediction we immunostained COS-7 cells treated with 
sortilin siRNA with anti-prosaposin, anti-GM2AP and 
anti-cathepsin B antibodies. Therefore, cargo that 
requires sortilin to be sorted to the lysosomes should be 
absent from or exhibit reduced immunostaining in the 
punctate structures. Conversely, cargo that did not 
depend on sortilin should continue to be visible in 
punctate structures. As predicted, prosaposin (Fig. 1.5) 
and GM2A P  w e r e  a b s e n t  f r o m  p u n c t a t e  s t r u c t u r e s  o f  
siRNA treated cells, while cathepsin B was not 
confirming a role for sortilin in the trafficking of SAPs to 
the lysosomal compartment (6). 
 
Use of hairpin RNAi 
 
Inactivation of genes with conventionally synthesized 
siRNAS may encounter several problems such as 
relatively high background levels produced by cells that 
do not incorporate the siRNA probe. Similarly, time 
constraints due to the transient nature of this silencing 
approach may affect the outcome of some experiments 
(15, 16). A recent technology that represents an 
improvement to these problems is the use of plasmids 
that express functional siRNAs for long-term studies 
(17). Since plasmids contain antibiotic resistant genes it is 
also possible to select successfully transfected cells and 
therefore to significantly lower the background 
produced by non-transfected cells (17).  
 
Using this approach we have created a COS-7 cell line 
transfected with the pSilencer 3.1 H1-neo vector from 
Ambion that contained a subcloned sortilin siRNA 
template oligonucleotide (sequence 1). The subcloned 
sequence included two complementary regions that 
permit the refolding of the transcribed RNA into a 
double-stranded region and a connecting stem (shRNA). 
The production of shRNA triggers Dicer cleavage and 
leads to the silencing of sortilin mRNA. To verify the 
expression of the shRNA and the knockdown of sortilin, 
RT-PCR and Western blotting of sortilin were conducted 
as for the in vitro siRNA experiments. Both analyses 
showed that the levels sortilin expression was decreased. 
These results were further confirmed by 
immunofluorescence and confocal microscopy (Figs. 1.7-
1.8). We expect to employ this sortilin deficient COS-7     
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cell line for proteomic analyses to determine if other 
soluble lysosomal proteins other than SAPs traffic to the 
lysosomes bound to sortilin. 
 
 
Fig. 1.1: COS-7 cell transfected with dominant-negative (truncated) sortilin fused to a myc-tag protein. Anti-myc antibody (green) colocalizes with anti-
Golgin antibody (red) in the perinuclear region of the cell. The overlay of both reactions yields yellow color indicating that truncated sortilin is retained 
in the Golgi apparatus. Magnification: x400. Fig. 1.2: COS-7 cell transfected with dominant-negative (truncated) sortilin fused to a myc-tag protein. 
Anti-myc antibody (green) colocalizes with anti-prosaposin antibody (red) in the perinuclear region of the cell. The overlay of both reactions yields 
yellow color indicating that prosaposin and sortilin were retained together in the Golgi apparatus. Magnification: x400. Fig. 1.3: COS-7 cell 
transfected with wild type sortilin construct (control) and immunostained with anti-Golgin (green) and anti-prosaposin (red) antibodies. The overlay 
shows yellow color in the perinuclear region and red granular in the cytoplasm typical of lysosomal staining. Magnification: x400. Fig. 1.4: COS-7 cell 
transfected with sortilin siRNA probe (sequence 1). The siRNA abolished the perinuclear staining of sortilin antibody (red). The overlay shows green 
fluorenscence only produced by the anti-Golgin antibody. Magnification: x400. Fig. 1.5: Cell transfected with a sortilin siRNA probe. The cell was 
stained with anti-sortilin (red) and anti-prosaposin (green) antibodies. The siRNA abolished the staining of sortilin and the punctate staining of the 
prosaposin antibody. Note that prosaposin is retained in the Golgi apparatus (green). Magnification: x400. Fig. 1.6: Control COS-7 cell (non 
transfected with siRNA) immunostained with anti-Golgin (green) and anti-prosaposin (red) antibodies. The red granular reaction is typical of 
prosaposin lysosomal staining. Magnification: x400. Fig. 1.7: COS-7 cell transfected with sortilin short hairpin interference RNA (shRNA) vector 
(sequence 1). The shRNA abolished the perinuclear staining of sortilin antibody (red). The overlay shows green fluorescence only, produced by the 
anti-Golgin antibody. Magnification: x400. Fig. 1.8: COS-7 cell transfected with empty vector (control) immunostained with anti-Golgin (green) and 
anti-prosaposin (red) antibodies. The red granular reaction is typical of prosaposin lysosomal staining. Magnification: x400.     
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CONCLUSIONS 
 
To study lysosomal trafficking pathways in living cells, 
several groups have taken advantage of mutant proteins 
and RNAi to disclose the role of proteins involved in 
these processes. Although both methods provide useful 
information on the function of sorting receptors, they 
also present some limitations. The introduction of 
mutant proteins as dominant-negative competitors into 
the cell is an excellent way of abolishing the function of a 
protein. In our hands, mutant sortilin lacking its 
carboxyl-terminal region demonstrated that sortilin is 
involved in the trafficking of the SAPs to the lysosomal 
compartment. However, the effect of mutant protein on 
other cellular functions should be a concern. For that 
matter it is important to examine control proteins with 
closely related cellular functions such as a protein or 
proteins involved in alternative trafficking pathways. 
Ideally, an alternative pathway that involves a different 
receptor should not be affected by the mutant protein. 
 
RNAi technology has also become a powerful tool in the 
investigation of gene function. This approach has made it 
possible to identify the role of novel genes much quicker 
than in the past. In our hands, we successfully 
determined the function of sortilin, a protein that 
interacts with coat proteins via its cytoplasmic domain 
but whose cargo remained largely unidentified. 
Knocking down sortilin interfered with the trafficking of 
SAPs to the lysosomes, suggesting a role for sortilin in 
the sorting and trafficking of SAPs to the lysosomal 
compartment. 
 
Although RNAi technology is useful, this method also 
presents some limitations. siRNAs used in cells offer a 
specific mechanism to target mRNA and knockdown a 
specific protein. However, the process is not as specific 
as initially thought. Short RNA inserts are required to 
prevent the cell from going through a viral response 
much like it would if being infected by a double stranded 
RNA virus (15). However, recent evidence suggests that 
the short RNA may cause some of the viral response to 
occur anyway. In addition, the specificity of the probe 
could be often in question. Although the probe is 
designed to bind to a single sequence, it is possible that it 
binds other sequences in a non-specific manner resulting 
in the knockdown of undesired proteins. This problem 
could be difficult to address since it is almost impossible 
to test the levels of all proteins in the cell. The best way 
to avoid both problems is to reduce the amount of siRNA 
to a minimum in the experiment. In practical terms, 
using low amounts of siRNA reduces the costs and 
increases the specificity of the experiment by avoiding 
non-specific knockdown of unrelated proteins and 
preventing the cell from undergoing a viral response. 
Although no specific quantities of siRNA will work for a 
given experiment, amounts in the range of 0.02 µM have 
worked well. In any case, each siRNA must be 
considered differently and should be tested at different 
concentrations. 
 
Finally, the combination of two or more approaches is 
the safest way to overcome the deficiency of a single 
method. In our case the use of dominant-negative 
mutants and siRNA have allowed us to characterize the 
role of sortilin in the sorting of SAPs. However, it is 
possible that sortilin is also involved in the sorting of 
other soluble lysosomal proteins. Currently, it is well 
accepted that soluble hydro l a s e s  m u s t  b i n d  t o  t h e  
mannose-6-phosphate receptor (M6P-R) to exit from the 
Golgi apparatus and in fact M6P-R is considered  the 
main lysosomal sorting receptor. Nevertheless, a number 
of laboratories have demonstrated that the lysosomes of 
I-cell disease (ICD) fibroblasts, resulting from a mutation 
in the phosphotransferase that adds mannose-6-
phosphate to hydrolases, have near normal levels of 
some lysosomal hydrolases, in addition, to the 
sphingolipid activator proteins prosaposin and GM2AP 
(16). This evidence suggests the existence of an 
alternative pathway. It is then possible that sortilin is 
involved in the targeting of hydrolases that do not use 
the M6P-R. This is the main focus of our laboratory. 
Consequently, we are pursuing the identification of all 
soluble hydrolases that use this alternative receptor by 
means of RNAi and proteomics. Our study will permit to 
identify other bona fide sortilin ligands and to predict 
the consequences of sortilin mutations. Nonetheless, the 
transient nature of siRNA technology, the relatively high 
levels of background and the time constraints due to the 
transient nature of silencing are problems that may affect 
the outcome of our experiments. Therefore, we have 
created a stable COS-7 cell line transfected with the 
pSilencer 3.1 H1 neo vector (Ambion) containing a 
selected siRNA template oligonucleotide (small hairpin 
interference RNA). As desired the levels of sortilin have 
been greatly suppressed. We intend to analyze the effect     
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of the elimination of sortilin using a proteomics 
approach. Immunochemically we shall verify the absence 
of cargo in the lysosomes of the established cell line. 
 
In conclusion, by using dominant-negative mutants and 
RNAi technology we were able to characterize a novel 
lysosomal sorting receptor (sortilin) involved in the 
alternative sorting of SAPs (prosaposin and GM2AP). 
The improvement of RNAi in conjunction with 
proteomics and other approaches should allow us to 
characterize the effects of sortilin inactivation on the 
sorting of soluble lysosomal proteins other than SAPs 
and to determine if sortilin is responsible of a more 
general mechanism of lysosomal sorting. 
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PROTOCOLS 
 
DEAE/Dextran chloroquine phosphate method for 100 mm plates 
 
Day 1: Plate out cells in serum free medium (5 X 105 per 100 mm culture plate) and incubate overnight 
Day 2: Prepare the following solutions before proceeding: 
•  10% DMSO in sterile PBS 
•  250 mg chloroquine phosphate in 5 ml serum free medium 
•  250 mg DEAE/dextran in 5 ml  
1.  Mix 50 µl of DEAE/dextran and 10 µl of chloroquine phosphate into 10 ml of serum free media. Add 25 µg of 
DNA. 
2.  Aspirate medium from cells and wash with sterile PBS or medium to remove dead cells 
3.  Replace with transfection solution mixed previously and incubate for 4 hours at 37°C  
4.  After 4 hour incubation, shock cells with 10% DMSO for 1 minute per plate 
5.  Wash plates with sterile PBS twice and replace with fresh DMEM containing fetal calf serum and antibiotics 
6.  Incubate for 48-72 hours 
Day 4 or 5: Analyze cells via immunostaining and Western blotting 
 
Hairpin RNAi  
 
siRNA template sequences can be sent to the Descript Corporation (Piscataway, NJ, USA) in order to be cloned into the 
pSilencer vector from Ambion, or cloned in your lab into the vector as follows: 
 
1.  Annealing. Reaction must be prepared according to Ambion protocol. Incubate the reagents at 90°C for 3 minutes 
and then cool the preparation to 37°C in a water bath for 1 hour. 
2.  Ligation of annealed siRNA template insert into pSilencer vector. Use a 20µl Rapid Ligation system (Roche, Laval, 
QC) according to the manufacturer’s instructions. A 3:1 ratio of insert to vector must be used. 
3.  Amplification of the ligated pSilencer vector. Use 2µl of pSilencer with the siRNA template and a pSilencer control 
vector with no insert to transform DHα5 E. coli (Bio S&T, Montreal, QC) according to manufacturer’s protocol onto 
LB plates containing 50µg/ml of ampicillin. Plates where the plus-insert ligation yield 5-10 fold more colonies than 
the minus-insert ligation must be used to harvest 4-6 colonies from which vector is purified according to 
specifications of a Qiagen HiSpeed Plasmid Midi Purification Kit. 
4.  Identification of clones with the hairpin siRNA insert. Digest 25µg of plasmid with BamH1 and HindIII restriction 
enzymes according to Sigma’s protocol (St. Louis, MO, USA). 
5.  Digestion products must be analyzed on a 10% PAGE gel. Visualize siRNA template insert (66bp and a 4486kb 
vector band). 
6.  Identification of positive clones must be confirmed by sequencing. 
  
Transfection into COS-7 cells 
 
1.  Plate 0.5 x 105 cells in a 24 well plate and transfect them with Lipofectamine 2000 as described by Invitrogen. Mix 
0.9µg of DNA and 2µl of Lipofectamine in serum-free DMEM medium (GIBCO). After 24 hours post-transfection, 
replace the growth medium with serum-containing medium. 
2.  Two days subsequent to transfection cells should be transferred to a 6-well plate and siRNA positive cells must be 
selected with 0.75 mg/ml of neomycin for 10-13 days. 
3.  The efficiency of the knockdown must be assessed by RT-PCR and Western blotting. 